The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Abstract
BACKGROUND: The widespread use of prostate‐specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA‐based screening has resulted in a stage migration to more organ‐confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so‐called “normal” range. METHODS: The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS: The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA‐based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high‐grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS: To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationProstate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Self-citationMeasurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Random Systematic Versus Directed Ultrasound Guided Transrectal Core Biopsies of the Prostate
Hodge, K. K., McNeal, J. E., Terris, M. K., & Stamey, T. A. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)38664-0 · Cited by 1,571
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.270.7.860 · Cited by 1,266
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Results of Conservative Management of Clinically Localized Prostate Cancer
Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J.-E., Adolfsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livne, P. M., & Warner, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300403 · Cited by 928
Purification of a Human Prostate Specific Antigen
Wang, M. C., Valenzuela, L. A., Murphy, G. P., & Chu, T. M. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.100 · Cited by 825
A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer
Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J. O., Folmerz, P., Häggman, M., Andersson, S.-O., Spångberg, A., Busch, C., Nordling, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012794 · Cited by 817
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.1993.03510070082041 · Cited by 807
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Cooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C., & Kidd, D. D. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40211-4 · Cited by 767
Lilja, H. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112185 · Cited by 734
The Role of Increasing Detection in the Rising Incidence of Prostate Cancer
Potosky, A. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310046028 · Cited by 674
Hankey, B. F., Feuer, E. J., Clegg, L. X., Hayes, R. B., Legler, J. M., Prorok, P. C., Ries, L. A., Merrill, R. M., & Kaplan, R. S. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.12.1017 · Cited by 652
Screening for Prostatic Carcinoma with Prostate Specific Antigen
Brawer, M. K., CHETNER, M. P., Beatie, J., Büchner, D. M., Vessella, R. L., & Lange, P. H. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37401-3 · Cited by 612
Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Bruzek, D. J., Rock, R. C., Brendler, C. B., & Walsh, P. C. (1988) · The Journal of Urology · doi:10.1016/s0022-5347(17)42630-9 · Cited by 573
PURIFICATION OF A HUMAN PROSTATE SPECIFIC ANTIGEN
WANG, M. C., VALENZUELA, L. A., MURPHY, G. P., & CHU, T. M. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)65270-6 · Cited by 550
Serial Prostatic Biopsies in Men with Persistently Elevated Serum Prostate Specific Antigen Values
Keetch, D. W., Catalona, W. J., & Smith, D. S. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35304-1 · Cited by 546
Study of Prediagnostic Selenium Level in Toenails and the Risk of Advanced Prostate Cancer
Yoshizawa, K., Willett, W. C., Morris, S. J., Stampfer, M. J., Spiegelman, D., Rimm, E. B., & Giovannucci, E. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1219 · Cited by 536
Clinical use of Prostate Specific Antigen in Patients with Prostate Cancer
Hudson, M. A., Bahnson, R. R., & Catalona, W. J. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)38972-3 · Cited by 491
Amirimani, B., Walker, A. H., Weber, B. L., & Rebbeck, T. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1588 · Cited by 465
Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study
Hoffman, R. M., Gilliland, F. D., Eley, J. W., Harlan, L. C., Stephenson, R. A., Stanford, J. L., Albertson, P. C., Hamilton, A. S., Hunt, W. C., & Potosky, A. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.5.388 · Cited by 441
Qu, Y., Adam, B.-L., Yasui, Y., Ward, M. D., Cazares, L. H., Schellhammer, P. F., Feng, Z., Semmes, O. J., & Wright, G. L. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.10.1835 · Cited by 433
Amling, C. L., Riffenburgh, R. H., Sun, L., Moul, J. W., Lance, R. S., Kusuda, L., Sexton, W. J., Soderdahl, D. W., Donahue, T. F., Foley, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.132 · Cited by 385
Freedland, S. J., Aronson, W. J., Kane, C. J., Presti, J. C., Amling, C. L., Elashoff, D., & Terris, M. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.181 · Cited by 384
Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., & Malkowicz, S. B. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1225 · Cited by 360
Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., & Reichardt, J. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11282-5 · Cited by 314
Sensabaugh, G. (1978) · Journal of Forensic Sciences · doi:10.1520/jfs10659j · Cited by 286
Prostate-Specific Antigen Values at the Time of Prostate Cancer Diagnosis in African-American Men
Moul, J. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530160029029 · Cited by 271
Body mass index and risk of prostate cancer in U.S. health professionals
Giovannucci, E., Rimm, E. B., Liu, Y., Leitzmann, M., Wu, K., Stampfer, M. J., & Willett, W. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg009 · Cited by 258
Jacobsen, S. J. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530180039027 · Cited by 225
CARVALHAL, G. F., SMITH, D. S., MAGER, D. E., RAMOS, C., & CATALONA, W. J. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61785-3 · Cited by 225
Farkas, A., Schneider, D., Perrotti, M., Cummings, K. B., & Ward, W. S. (1998) · Urology · doi:10.1016/s0090-4295(98)00242-8 · Cited by 202
Follow-up Prostate Cancer Treatments After Radical Prostatectomy: a Population-Based Study
Lu-Yao, G. L., Potosky, A. L., Albertsen, P. C., Wasson, J. H., Barry, M. J., & Wennberg, J. E. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.166 · Cited by 196
Watkins Bruner, D., Moore, D., Parlanti, A., Dorgan, J., & Engstrom, P. (2003) · International Journal of Cancer · doi:10.1002/ijc.11466 · Cited by 190
Ellis, W. J., Chetner, M. P., Preston, S. D., & Brawer, M. K. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32460-6 · Cited by 170
Thompson, I. M., Tangen, C. M., Tolcher, A., Crawford, E. D., Eisenberger, M., & Moinpour, C. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.219 · Cited by 165
Self-citationCarter, H. B., Chan, D. W., Pearson, J. D., Guess, H. A., Waclawiw, Z., Walsh, P. C., & Metter, E. J. (1995) · Urology · doi:10.1016/s0090-4295(99)80049-1 · Cited by 152
Stage at presentation and survival of white and black patients with prostate carcinoma
Brawn, P. N., Johnson, E. H., Kuhl, D., Riggs, M. W., Speights, V. O., Johnson, C. F., Pandya, P. P., Lind, M. L., & Bell, N. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2569::aid-cncr2820710822>3.0.co;2-r · Cited by 148
Reís, S. E., Costantino, J. P., Wickerham, D. L., Tan-Chiu, E., Wang, J., & Kavanah, M. T. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.1.16 · Cited by 146
Hara, M., Koyanagi, Y., Inoue, T., & Fukuyama, T. (1971) · PubMed · Cited by 145
The Prostate Cancer Intervention Versus Observation Trial (PIVOT).
Wilt, T. J., & Brawer, M. K. (1997) · PubMed · Cited by 130
DAVIS, M., Sofer, M., Kim, S. S., & Soloway, M. S. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(01)69087-6 · Cited by 129
Amling, C. L., Kane, C. J., Riffenburgh, R. H., Ward, J. F., Roberts, J. L., Lance, R. S., Friedrichs, P. A., & Moul, J. W. (2001) · Urology · doi:10.1016/s0090-4295(01)01373-5 · Cited by 128
The association of fatty acids with prostate cancer risk
Newcomer, L. M., King, I., Wicklund, K., & Stanford, J. L. (2001) · The Prostate · doi:10.1002/pros.1070 · Cited by 120
Isolation and Characterization of Two Specific Antigens of Human Seminal Plasma
Li, T. S., & Beling, C. G. (1973) · Fertility and Sterility · doi:10.1016/s0015-0282(16)39496-1 · Cited by 118
Dietary fat and prostate cancer survival
Meyer, F., Bairati, I., Shadmani, R., Fradet, Y., & Moore, L. (1999) · Cancer Causes & Control · doi:10.1023/a:1008913307947 · Cited by 114
The results of a five-year early prostate cancer detection intervention
Mettlin, C. J., Murphy, G. P., Babaian, R. J., Chesley, A. E., Kane, R. A., Littrup, P. J., Mostofi, F. K., Ray, P. S., Shanberg, A. M., Toi, A., et al. (1996) · Cancer · Cited by 108
Nomograms as predictive models
Eastham, J. A., Kattan, M. W., & Scardino, P. T. (2002) · Seminars in Urologic Oncology · doi:10.1053/suro.2002.32936 · Cited by 101
Ornstein, D. K., Smith, D. S., Rao, G. S., et al. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64708-6 · Cited by 89
Ten-Year Survival in Patients with Metastatic Prostate Cancer
Tangen, C. M., Faulkner, J. R., Crawford, E. D., Thompson, I. M., Hirano, D., Eisenberger, M. A., & Hussain, M. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.011 · Cited by 85
Self-citationProstate cancer in black and white Americans
Reddy, S., Shapiro, M. A., Morton, R., & Brawley, O. W. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1022216119066 · Cited by 71
Androgen Receptor Length Polymorphism Associated with Prostate Cancer Risk in Hispanic Men
Balic, I., GRAHAM, S. T., Troyer, D. A., Higgins, B., Pollock, B. H., Johnson‐Pais, T. L., Thompson, I. M., & Leach, R. J. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64364-9 · Cited by 70
Self-citationEastham, J. A., May, R. A., Whatley, T., Crow, A., Venable, D. D., & Sartor, O. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.756 · Cited by 68
Bauer, J. J., Srivastava, S. K., Connelly, R. R., Sesterhenn, I. A., Preston, D., McLeod, D. G., & Moul, J. W. (1998) · Urology · doi:10.1016/s0090-4295(98)00103-4 · Cited by 66
Ultrasound-guided prostate biopsy Biopty gun superior to aspiration
Ragde, H., Aldape, H. C., & Bagley, C. M. (1988) · Urology · doi:10.1016/s0090-4295(98)90029-2 · Cited by 60
Is Ethnicity an Independent Predictor of Prostate Cancer Recurrence After Radical Prostatectomy?
Grossfeld, G. D., Latini, D. M., Downs, T. M., Lubeck, D. P., Mehta, S. S., & Carroll, P. R. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64179-1 · Cited by 58
Dietary Fat and Prostate Cancer Progression and Survival
Fradet, Y., Meyer, F. C. O., Bairati, I., Shadmani, R., & Moore, L. (1999) · European Urology · doi:10.1159/000019913 · Cited by 51
Diet, Micronutrients, and the Prostate Gland
Thomas, J. A. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1999.tb06932.x · Cited by 42
DEFERRED TREATMENT OF LOCALLY ADVANCED NONMETASTATIC PROSTATE CANCER: A LONG-TERM FOLLOWUP
Adolfsson, J., Steineck, G., & Hedlund, P. O. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61936-0 · Cited by 37
Abdalla, I., Ray, P., Ray, V., Vaida, F., & Vijayakumar, S. (1999) · American Journal of Clinical Oncology · doi:10.1097/00000421-199912000-00001 · Cited by 27
Molecular Epidemiology of Androgen-Metabolic Loci in Prostate Cancer: Predisposition and Progression
Makridakis, N. M., & Reichardt, J. K. V. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000107844.78769.35 · Cited by 21
Cited by
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Chen, K.-I., Li, B.-R., & Chen, Y.-T. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.001 · Cited by 645
Decramer, S., de Peredo, A. G., Breuil, B., Mischak, H., Monsarrat, B., Bascands, J.-L., & Schanstra, J. P. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r800001-mcp200 · Cited by 450
Multicolor quantum dots for molecular diagnostics of cancer
Smith, A. M., Dave, S., Nie, S., True, L., & Gao, X. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.6.2.231 · Cited by 348
Metadata
- Authors
- Hernández, J., & Thompson, I. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-08-18
- Volume
- 101
- Issue
- 5
- Pages
- 894-904
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2100531189
- Cited by
- 527
- References
- 67
- FWCI
- 41.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.